The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Belyaev A.Yu.

Burdenko Neurosurgical Center

Shugai S.V.

Burdenko Neurosurgical Center

Kobyakov G.L.

Burdenko Neurosurgical Center

Strunina Yu.V.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Pronin I.N.

Burdenko Neurosurgical Center

Usachev D.Yu.

Burdenko Neurosurgical Center

Anaplastic pleomorphic xanthoastrocytoma — single-center analysis of 42 patients

Authors:

Belyaev A.Yu., Shugai S.V., Kobyakov G.L., Strunina Yu.V., Batalov A.I., Pronin I.N., Usachev D.Yu.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2022;86(2): 45‑54

DOI: 10.17116/neiro20228602145

Views: 5194

Downloaded: 134

Download PDF (RU)
Download PDF
Contact the author
Table of contents

ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA — SINGLE-CENTER ANALYSIS OF 42 PATIENTS
ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA — SINGLE-CENTER ANALYSIS OF 42 PATIENTS

To cite this article:

Belyaev AYu, Shugai SV, Kobyakov GL, Strunina YuV, Batalov AI, Pronin IN, Usachev DYu. Anaplastic pleomorphic xanthoastrocytoma — single-center analysis of 42 patients. Burdenko's Journal of Neurosurgery. 2022;86(2):45‑54. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20228602145

Подписка 2025-2 (Burdenko's Journal of Neurosurgery)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Long-term clinical outcomes of patients with loca­lly adva­nced gastric adenocarcinoma after two indu­ction cycles of chemotherapy acco­rding to the FLOT regi­men followed by chemoradiotherapy and radi­cal surgery. P.A. Herzen Journal of Onco­logy. 2025;(2):5-12

Anaplastic pleomorphic xanthoastrocytoma is a rare tumor. There are still no objective data on the incidence of its diagnosis.

OBJECTIVE

To study neuroimaging, morphological features of tumors, as well as factors affecting treatment and prognosis.

MATERIAL AND METHODS

A retrospective study enrolled 42 patients operated on at the Burdenko Neurosurgery Center between 2003 and 2020. MR characteristics of anaplastic pleomorphic xanthoastrocytoma were analyzed. All patients underwent resection of tumor (total resection in 83.3% of cases). Redo surgeries were performed in 1/3 of patients. Mutational status of BRAF V600E was assessed in all patients. Adjuvant radio- and chemotherapy was performed in more than 80% of cases. Tyrosine kinase inhibitors were administered in 19% of cases. The follow-up period was 152 months (median 34 months).

RESULTS

We found no pathognomonic MR signs of this disease. Indeed, anaplastic pleomorphic xanthoastrocytoma have the same signal characteristics as other malignant gliomas. The BRAF V600E mutation status was positive in 54.8% of cases. None patient had IDH-1 mutation. Mean Ki-67 index was 12.5%. The overall survival was 79 months (range 4—152). Seven (17%) patients are alive for more than 90 months. Only Ki-67 index and BRAF mutation significantly influenced the treatment prognosis and overall survival regardless the use of tyrosine kinase inhibitors.

CONCLUSION

Such well-known factors for malignant glioma as patient age, total resection and adjuvant therapy did not significantly affect overall survival. Perhaps, searching for new molecular genetic features will reveal additional significant factors of prognosis in patients with anaplastic pleomorphic xanthoastrocytoma.

Keywords:

anaplastic pleomorphic xanthoastrocytoma
BRAF V600 E mutation
resection quality
overall survival

Authors:

Belyaev A.Yu.

Burdenko Neurosurgical Center

Shugai S.V.

Burdenko Neurosurgical Center

Kobyakov G.L.

Burdenko Neurosurgical Center

Strunina Yu.V.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Pronin I.N.

Burdenko Neurosurgical Center

Usachev D.Yu.

Burdenko Neurosurgical Center

Received:

04.10.2021

Accepted:

28.01.2022

List of references:

  1. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: A distinctive meningocerebral glioma of young subjects with relatively favorable prognosis A study of 12 cases. Cancer. 1979;44(5):1839-1852. https://doi.org/10.1002/1097-0142(197911)44:5<1839::AID-CNCR2820440543>3.0.CO;2-0 "> 3.0.CO;2-0" target="_blank">https://doi.org/10.1002/1097-0142(197911)44:5<1839::AID-CNCR2820440543>3.0.CO;2-0
  2. Wasdahl DA, Scheithauer BW, Andrews BT, Jeffrey RA. Cerebellar pleomorphic xanthoastrocytoma: Case report. Neurosurgery. 1994;35(5):947-951.  https://doi.org/10.1227/00006123-199411000-00022
  3. Chapman EM, Ranger A, Lee DH, Hammond RR. A 15 year old boy with a posterior fossa tumor. Brain Pathology. 2009;19(2):349-352.  https://doi.org/10.1111/j.1750-3639.2009.00281.x
  4. Luna LP, da Ponte IM, Oliveira IB, Ramos F, Gerson G. Pleomorphic xanthoastrocytoma in the posterior fossa: a case report with advanced neuroimaging findings. Clinical Imaging. 2020;63:30-34.  https://doi.org/10.1016/j.clinimag.2020.02.010
  5. Herpers MJHM, Freling G, Beuls EAM. Pleomorphic xanthoastrocytoma in the spinal cord. Case report. Journal of Neurosurgery. 1994;80(3):564-569.  https://doi.org/10.3171/jns.1994.80.3.0564
  6. Zarate JO, Sampaolesi R. Pleomorphic xanthoastrocytoma of the retina. American Journal of Surgical Pathology. 1999;23(1):79-81.  https://doi.org/10.1097/00000478-199901000-00008
  7. Iwaki T, Fukui M, Kondo A, Matsushima T, Takeshita I. Epithelial properties of pleomorphic xanthoastrocytomas determined in ultrastructural and immunohistochemical studies. Acta Neuropathologica. 1987;74(2):142-150.  https://doi.org/10.1007/BF00692844
  8. Ida CM, Rodriguez FJ, Burger PC, Caron AA, Jenkins SM, Spears GM, Aranguren DL, Lachance DH, Giannini C. Pleomorphic xanthoastrocytoma: Natural history and long-term follow-up. Brain Pathology. 2015;25(5):575-586.  https://doi.org/10.1111/bpa.12217
  9. Hirose T, Ishizawa K, Sugiyama K, Kageji T, Ueki K, Kannuki S. Pleomorphic xanthoastrocytoma: A comparative pathological study between conventional and anaplastic types. Histopathology. 2008;52(2):183-193.  https://doi.org/10.1111/j.1365-2559.2007.02926.x
  10. Giannini C, Scheithauer BW, Burger PC, Brat DJ, Wollan PC, Lach B, O’Neill BP. Pleomorphic xanthoastrocytoma: What do we really know about it. Cancer. 1999;85(9):2033-2045. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.0.CO;2-Z "> 3.0.CO;2-Z" target="_blank">https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.0.CO;2-Z
  11. Korshunov A, Golanov A. Pleomorphic xanthoastrocytomas: Immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute. Journal of Neuro-Oncology. 2001;52(1):63-72.  https://doi.org/10.1023/A:1010648006319
  12. Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathology and Applied Neurobiology. 2018;44(2):139-150.  https://doi.org/10.1111/nan.12432
  13. Marton E, Feletti A, Orvieto E, Longatti P. Malignant progression in pleomorphic xanthoastrocytoma: Personal experience and review of the literature. Journal of the Neurological Sciences. 2007;252(2):144-153.  https://doi.org/10.1016/j.jns.2006.11.008
  14. Kahramancetin N, Tihan T. Aggressive behavior and anaplasia in pleomorphic xanthoastrocytoma: a plea for a revision of the current WHO classification. CNS Oncology. 2013;2(6):523-530.  https://doi.org/10.2217/cns.13.56
  15. Tonse R, Gupta T, Epari S, Shastri JG, Gurav M, Bano N, Jalali R. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. Journal of Neuro-Oncology. 2018;136(2):343-350.  https://doi.org/10.1007/s11060-017-2658-7
  16. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica. 2011;121(3):397-405.  https://doi.org/10.1007/s00401-011-0802-6
  17. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS One. 2011;6(3):e17948. https://doi.org/10.1371/journal.pone.0017948
  18. Rodrigues A, Bhambhvani H, Medress ZA, Malhotra S, Hayden-Gephart M. Differences in treatment patterns and overall survival between grade II and anaplastic pleomorphic xanthoastrocytomas. Journal of Neuro-Oncology. 2021;153(2):321-330.  https://doi.org/10.1007/s11060-021-03772-0
  19. Rutkowski MJ, Oh T, Niflioglu GG, Safaee M, Tihan T, Parsa AT. Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series. World Neurosurgery. 2016;95:368-374.  https://doi.org/10.1016/j.wneu.2016.07.068
  20. Liu J, Sun Y, Liu X. Anaplastic Pleomorphic Xanthoastrocytoma: A Case Report and Literature Review. International Journal of General Medicine. 2020;13:1581-1587. https://doi.org/10.2147/IJGM.S285989
  21. Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clinical and Translational Oncology. 2016;18(11):1062-1071. https://doi.org/10.1007/s12094-016-1497-x
  22. Hong JB, Roh TH, Kang SG, Kim SH, Moon JH, Kim EH, Ahn SS, Choi HJ, Cho J, Suh C-O, Chang JH. Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas. Cancer Research and Treatment. 2020;52(4):1041-1049. https://doi.org/10.4143/crt.2020.057
  23. Choudry UK, Khan SA, Qureshi A, Bari E. Primary anaplastic pleomorphic xanthoastrocytoma in adults. Case report and review of literature. International Journal of Surgery Case Reports. 2016;27:183-188.  https://doi.org/10.1016/j.ijscr.2016.08.022
  24. Vu TM, Liubinas Sv, Gonzales M, Drummond KJ. Malignant potential of pleomorphic xanthoastrocytoma. Journal of Clinical Neuroscience. 2012;19(1):12-20.  https://doi.org/10.1016/j.jocn.2011.07.015
  25. Brown NF, Carter T, Mulholland P. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma. CNS Oncology. 2017;6(1):5-9.  https://doi.org/10.2217/cns-2016-0031
  26. Lee EQ, Ruland S, Leboeuf NR, Wen PY, Santagata S. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. Journal of Clinical Oncology. 2016;34(10):87-89.  https://doi.org/10.1200/JCO.2013.51.1766
  27. Thomas AA, Tucker SM, Nelson CJ, Nickerson JP, Durham SR, Homans AC. Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab. Pediatric Blood and Cancer. 2019;66(1):e27465. https://doi.org/10.1002/pbc.27465
  28. Schmidt Y, Kleinschmidt-Demasters BK, Aisner DL, Lillehei KO, Damek D. Anaplastic PKSA in adults: Case series with clinicopathologic and molecular features. Journal of Neuro-Oncology. 2013;111(1):59-69.  https://doi.org/10.1007/s11060-012-0991-4
  29. Lubansu A, Rorive S, David P, Sariban E, Seligmann R, Brotchi J, Pirotte B. Cerebral anaplastic pleomorphic xanthoastrocytoma with meningeal dissemination at first presentation. Child’s Nervous System. 2004;20(2):119-122.  https://doi.org/10.1007/s00381-003-0854-6
  30. Okazaki T, Kageji T, MatsuzaKi K, Horiguchi H, Hirose T, Watanabe H, Ohnishi T, Nagahiro S. Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis — A pediatric case report and review of the literature. Journal of Neuro-Oncology. 2009;94(3):431-437.  https://doi.org/10.1007/s11060-009-9876-6

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.